Derbycare

DerbyCare is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological and immunological diseases. Headquartered in Suzhou, China, the company specializes in small molecule inhibitors targeting the JAK/STAT pathway to treat conditions such as atopic dermatitis and chronic pruritus. Their lead candidate, DC-001, is a topical JAK inhibitor designed to provide effective relief with minimal systemic exposure. The company's pipeline also includes oral formulations like DC-002, which are being evaluated for indications such as alopecia areata and psoriasis. DerbyCare aims to address significant unmet medical needs in the global dermatology market through its dedicated R&D efforts and strategic focus on high-potency, low-toxicity compounds. The firm is backed by prominent venture capital investors and maintains a strong presence in the Suzhou BioBay industrial park.